Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Chimeric antigen receptor T (CAR-T) cell therapy shows limited efficacy in solid tumors, partly owing to poorly defined tumor-intrinsic resistance mechanisms. Here we show that the epigenetic regulator BAZ2A drives resistance to CD70-targeted CAR-T therapy by reprogramming tumor lipid metabolism.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.